The FDA has granted breakthrough device status to Efemoral Medical’s novel vascular scaffold system for the treatment of chronic limb-threatening ischemia. The system, called Efemoral Vascular Scaffold System, is designed to restore normal vessel diameter across all lesion lengths and morphologies for above-the-knee interventions. It uses a unique design of alternating, dissolvable, drug-eluting scaffolds and is being tested in the first-in-human EFEMORAL I trial in New Zealand and Australia. The company has also begun developing a device to treat below-the-knee arteries in this population. Breakthrough device designation expedites the development and review of devices intended to treat serious conditions with potentially substantial improvement over available devices.
Source link
FDA grants device for treatment of chronic limb-threatening ischemia breakthrough status
